Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multicenter, Randomized Controlled Study on the MA+AZA Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)

NCT06345365 is registered in ClinicalTrials.gov with Zhongnan Hospital as lead sponsor.

NCT NCT06345365
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06345365 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multicenter, Randomized Controlled Study on the MA+AZA Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)
Lead sponsor
Zhongnan Hospital
Phase
Phase 3
Overall status
Recruiting
Start date
January 18, 2024
Completion date
December 31, 2028
Enrollment
154 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukaemia